This current invention provides methods and agents for preventing and treating autoimmune and lymphoproliferative disease by targeting pathogenic age-associated B cells as well as methods of detecting these pathogenic age-associated B cells as a method of diagnosing and predicting autoimmune disease and other lymphoproliferative and chronic inflammatory disorders.

The current invention also provides targets for drug development and basic research for autoimmune diseases and other lymphoproliferative and chronic inflammatory disorders.

This current invention provides methods and agents for preventing and treating autoimmune and lymphoproliferative disease by targeting pathogenic age-associated B cells as well as methods of detecting these pathogenic age-associated B cells as a method of diagnosing and predicting autoimmune disease and other lymphoproliferative and chronic inflammatory disorders.

The current invention also provides targets for drug development and basic research for autoimmune diseases and other lymphoproliferative and chronic inflammatory disorders.

The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.

The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.

The present disclosure relates to a functional food composition for improving muscular endurance and relieving fatigue containing Paeoniae japonica, Astragalus membranaceus, Cnidium officinale, velvet antler and Platycodon grandiflorum. Since the composition contains 6 kinds of herbal medicinal materials, the quality of the composition may be advantageously maintained, and the composition may improve muscular endurance and reduce fatigue by increasing muscle glycogen levels.

The present invention relates to pre-formulations comprising: a) at least one di-acyl lipid; b) at least one phospholipid; c) at least one biocompatible, organic solvent; d) an alkyl ammonium EDTA salt; and e) at least one somatostatin receptor agonist;
wherein the pre-formulation has a water content in the range of 0 to 1.0 wt %.

The invention further relates to methods of treatment comprising administration of such pre-formulations, to pre-filled administration devices and kits containing the formulations, to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation.

Disclosed herein are methods, compositions, kits, and agents useful for inducing β cell maturation, and isolated populations of SC-β cells for use in various applications, such as cell therapy.

Compositions and methods for regenerating pancreatic islet viability and/or cell proliferation in vitro, ex vivo, and/or in vivo; and/or for regenerating glucose-stimulated insulin secretion; and/or for regenerating viability and/or cell proliferation of a transplanted pancreatic islets; and/or for preventing and/or inhibiting rejection of a transplanted islets; and/or for pancreatic islet transplantation; and/or for treating a symptom of a condition, disorder, or disease associated with abnormal insulin responsiveness to glucose are provided. In some embodiments, the compositions include a peptide and/or a pharmaceutically acceptable salt thereof, and/or a biologically active fragment, analog, or derivative thereof, wherein the peptide, the pharmaceutically acceptable salt thereof, and/or the biologically active fragment, analog, or derivative thereof has an amino acid sequence of any of SEQ ID NOs: 1-60, or any combination thereof.

Use of a dietary fibre material extracted from sugar cane in the manufacture of a food product that is formulated to ameliorate the effects of diabetes.

This invention involves repurposing the use of TAK-448 in NAFLD or NASH. In this study, a diet-induced mouse model of NAFLD was used to demonstrate that a hepatic knock-out of Kiss1r promotes steatosis. Moreover, infusion of the KP analog (TAK-488) in obese, wild-type diabetic mice protects against disease progression. Thus, the present invention provides a therapy for metabolic disorders such as NAFLD and NASH through the administration of TAK-488, a long-lasting synthetic analog of kisspeptin-10, a naturally occurring peptide found in the blood.